Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
University of Pittsburgh
Study ID
NCT06475807
Status
Recruiting
Apply to this trial

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • High-fermented food — DIETARY_SUPPLEMENT
    Step 1: patients will consume high-fermented food
  • High fiber supplementation — DIETARY_SUPPLEMENT
    Step 2: High fiber supplementation

Study Details

This pilot trial will study the potential impact of two distinct dietary interventions with sequential use of high-fermented foods and high-fiber supplements on the gut microbiome and antitumor immunity in patients with melanoma and non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors. The trial aims to understand how dietary changes affect the composition and function of the gut microbiome, together with immunological and metabolomic markers in serum in patients with melanoma and NSCLC who are undergoing standard-of-care treatment with a PD-1/PD-L1 Inhibitors (neoadjuvant, adjuvant or consolidation)

Key Dates

Start date
Jul 17, 2024
Status verified
Mar 2026
Primary completion
Jun 30, 2030
Completion
Jun 30, 2030

Study Design

Enrollment
70 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: high-fermented food + high fiber supplementation
    Step 1: patients will consume high-fermented food Step 2: High fiber supplementation

Primary Outcome Measure

Change in cell frequency of gut microbiota composition [ Time Frame: Up to 14 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UPMC Hillman Cancer CenterPittsburghPennsylvania15232
Hassane M Zarour, MD
[email protected]
(412) 623-3272

Find similar trials in Pittsburgh, PA

By research site
UPMC Hillman Cancer Center· Pittsburgh, PA

Related Studies